A second study evaluating the impact of GLP-1RAs on 13 obesity-related cancers in patients with T2DM found that compared to insulin, GLP-1RAs were associated with a lower risk in 10/13 (gallbladder, meningioma, pancreas, liver, ovarian, colorectal, multiple myeloma, esophageal, endometrial, and kidney) cancers, a non-significantly lower risk in stomach cancer, and no significant effect on the risk of postmenopausal breast or thyroid cancer [40]. Here, INS is linked to obesity disorder.